● Recruiting

Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease

Condition: Fabry Disease · Sponsor: ISU Abxis Co., Ltd.

PhasePhase 3

Planned participants24

Who can joinAll sexes, 8 Years to no upper limit

Healthy volunteersNo

About this study

Evaluate the safety and efficacy of Fabagal® developed by ISU ABXIS Co., Ltd., which has similar efficacy to active comparator (Agalsidase beta).

This description comes directly from the study's public registry record.

Talk to the study team

Beomhee Lee · 1688-7575 · webmaster@amc.seoul.kr

Always discuss trial participation with your own doctor first.

Locations (3)

Philippine General Hospital	Manila, Philippines	Recruiting
St.Luke's Medical Center	Manila, Philippines	Recruiting
Seoul Asan Center	Seoul, Songpa-gu, South Korea	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06081062